Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

EMA Validates Swedish Orphan Biovitrum publ AB's Application for Orfadin Oral Suspension


Thursday, 22 Aug 2013 02:01am EDT 

Swedish Orphan Biovitrum publ AB announced that its application for Orfadin oral suspension has been validated by the European Medicines Agency (EMA). This new dosage form has been developed to facilitate the ease and accuracy in administration of the desired Orfadin dose to pediatric patients and to increase convenience for the patients and their caregivers. The oral suspension is included in a Pediatric Investigation Plan (PIP) agreed with EMA in March 2012. 

Company Quote

85.75
-0.25 -0.29%
11 Jul 2014